The 5-Hydroxytryptamine Receptor 2C pipeline drugs market research report outlays comprehensive information on the 5-Hydroxytryptamine Receptor 2C targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the 5-Hydroxytryptamine Receptor 2C pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Central Nervous System, Metabolic Disorders, Genetic Disorders, and Undisclosed which include the indications Schizophrenia, Unspecified Psychiatric Disorders, Obesity, Tuberous Sclerosis, Prader-Willi Syndrome (PWS), and Unspecified. It also reviews key players involved in 5-Hydroxytryptamine Receptor 2C targeted therapeutics development with respective active and dormant or discontinued products.
The 5-Hydroxytryptamine Receptor 2C pipeline targets constitutes close to 34 molecules. Out of which, approximately 31 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, and Discovery stages are 3, 6, 6, 11, and 5 respectively. Similarly, the universities portfolio in Phase I, Preclinical, and Discovery comprises 1, 1, and 1 molecule.
5-Hydroxytryptamine Receptor 2C overview
The 5-HT2C receptor is a subtype of the 5-HT receptor that binds to the neurotransmitter serotonin (5-hydroxytryptamine, 5-HT). It is a seven-transmembrane, G-protein coupled receptor that regulates key brain functions, including food intake, anxiety, stress response, sleep, mood, motor behavior, appetite, and endocrine secretion.
For a complete picture of 5-Hydroxytryptamine Receptor 2C’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
